^
Association details:
| Biomarker: | EML4-ALK variant 3 + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer
Published date:
07/18/2022
Excerpt:
Among the different ALK fusion genes, patients carrying the v3 variant experienced worse PFS outcome compared with other non-v3 fusions (P = 0.01) in response to first-line crizotinib. Profiling of the genetic landscape revealed TP53 as the most frequently co-mutated gene, alterations of which were associated with unfavorable outcome (P = 0.024)....In this study, through profiling of the mutational landscape of ALK-positive advanced NSCLCs both at baseline and disease progression, we characterized resistance mechanisms and molecular correlations of PFS in response to first-line crizotinib.
DOI:
https://doi.org/10.1016/j.lungcan.2022.07.011
